摘要
目的探讨心力衰竭患者血清脂联素(APN)的变化及阿托伐他汀干预的临床效果。方法将我院2011年1月至2012年6月收治的60例充血性心力衰竭患者随机分为研究组和对照组各30例。两组均给予常规治疗,研究组同时应用阿托伐他汀20 mg,1次/d,疗程均3个月,治疗前后应用酶联免疫吸附法检测两组APN水平,应用超声心电图检测左室射血分数(LVEF)、左室舒张末期内径(LVEDD)。结果①60例患者心功能Ⅱ、Ⅲ、Ⅳ级患者APN水平分别为(5.71±1.85)mg/L、(11.08±2.78)mg/L及(15.08±3.72)mg/L,心力衰竭患者APN水平随心功能恶化而逐渐升高(P<0.01)。②治疗前两组患者APN、LVEF、LVEDD比较差异无统计学意义(P>0.05)。治疗后两组患者LVEF明显升高,LVEDD、APN明显降低(P<0.05),治疗后研究组LVEF高于对照组,LVEDD、APN低于对照组,APN明显低于干预治疗前水平(P<0.05)。结论慢性心力衰竭患者血清脂联素水平异常升高,且随患者心功能恶化而逐渐升高,阿托伐他汀干预能有效提高患者心功能,降低血清脂联素水平。
Objective To explore the effect of atorvastatin intervention in the treatment of heart failure pa- tients, and to analyze the levels of serum adiponectin. Methods Sixty patients with congestive heart failure admitted to our hospital from January 2011 to June 2012 were selected, which were randomly divided into the study group and the control group, with 30 patients in each group. The two groups were both were given conventional treatment, and the study group added atorvastatin statin 20 mg, once daily for 3 months. The levels of APN were detected before and after treatment using enzyme-linked immunosorbent assay, and the left ventricular ejection fraction （LVEF）, left ventricu- lar end-diastolic diameter （LVEDD） were detected by ultrasound ECG. Results ① Among the 60 patients, APN levels in patients with grade Ⅱ,Ⅲ,Ⅳ cardiac function were （5.71±1.85） mg/L, （11.08±2.78） mg/L and （15.08±3.72） mg/L, respectively. The APN levels in patients with heart failure increased gradually with deteriorating of cardiac function （P〈0.01）. ② Before treatment, APN, LVEF, LVEDD showed no significant difference between the two groups （P〉0.05）. After treatment, LVEF was significantly increased, while LVEDD, APN significantly decreased （P〈0.05）. After treat- ment, LVEF in the study group was higher than that of the control group, while LVEDD, APN in the study group were lower. APN after intervention was significantly lower than that before intervention （P〈0.05）. Conclusion The serum adiponectin levels in chronic heart failure patients are abnormally elevated, and gradually increased with the deteriora- tion of cardiac function in patients. The atorvastatin intervention can improve heart function in patients and lower the serum adiponectin levels.
出处
《海南医学》
CAS
2013年第17期2507-2509,共3页
Hainan Medical Journal
